{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:52:37Z","timestamp":1760147557057,"version":"build-2065373602"},"reference-count":33,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key Research and Development Program in China","award":["2021YFC2301200","2021C03043","SKLID2020KF0420","2020D1284"],"award-info":[{"award-number":["2021YFC2301200","2021C03043","SKLID2020KF0420","2020D1284"]}]},{"name":"Zhejiang Provincial Key Research and Development Program","award":["2021YFC2301200","2021C03043","SKLID2020KF0420","2020D1284"],"award-info":[{"award-number":["2021YFC2301200","2021C03043","SKLID2020KF0420","2020D1284"]}]},{"DOI":"10.13039\/501100011441","name":"State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University","doi-asserted-by":"publisher","award":["2021YFC2301200","2021C03043","SKLID2020KF0420","2020D1284"],"award-info":[{"award-number":["2021YFC2301200","2021C03043","SKLID2020KF0420","2020D1284"]}],"id":[{"id":"10.13039\/501100011441","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major horizontal project of Zhejiang Shuren University","award":["2021YFC2301200","2021C03043","SKLID2020KF0420","2020D1284"],"award-info":[{"award-number":["2021YFC2301200","2021C03043","SKLID2020KF0420","2020D1284"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The development of an efficient and safe coronavirus disease 2019 (COVID-19) vaccine is a crucial approach for managing the severe acute respiratory disease coronavirus 2 (SARS-CoV-2) pandemic in light of current conditions. In this study, we produced a shortened segment of the optimized SARS-CoV-2 spike gene (2043 bp, termed S1) that was able to encode a truncated S1 protein. The protein was tested to determine if it could elicit efficient immunization in mice against SARS-CoV-2. The presence of the S1 protein was confirmed with immunofluorescence and Western blotting. An adenovirus vaccine bearing the S1 gene fragment (Ad-S1) was administered intramuscularly to mice four times over 4 weeks. SARS-CoV-2 S1 protein humoral immunity was demonstrated in all immunized mice. The serum from immunized mice demonstrated excellent anti-infection activity in vitro. A robust humoral immune response against SARS-CoV-2 was observed in the mice after vaccination with Ad-S1, suggesting that the adenovirus vaccine may aid the development of vaccines against SARS-CoV-2 and other genetically distinct viruses.<\/jats:p>","DOI":"10.3390\/vaccines11020429","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T06:09:21Z","timestamp":1676268561000},"page":"429","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Adenovirus Vaccine Containing Truncated SARS-CoV-2 Spike Protein S1 Subunit Leads to a Specific Immune Response in Mice"],"prefix":"10.3390","volume":"11","author":[{"given":"Keda","family":"Chen","sequence":"first","affiliation":[{"name":"Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danrong","family":"Shi","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5514-842X","authenticated-orcid":false,"given":"Chaonan","family":"Li","sequence":"additional","affiliation":[{"name":"Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongbiao","family":"Fang","sequence":"additional","affiliation":[{"name":"Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yikai","family":"Guo","sequence":"additional","affiliation":[{"name":"Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Jiang","sequence":"additional","affiliation":[{"name":"Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxuan","family":"Li","sequence":"additional","affiliation":[{"name":"Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Li","sequence":"additional","affiliation":[{"name":"Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hangping","family":"Yao","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12929-020-00703-5","article-title":"Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications","volume":"28","author":"Trougakos","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/jclinpath-2020-206658","article-title":"Gene of the month: The 2019-nCoV\/SARS-CoV-2 novel coronavirus spike protein","volume":"73","author":"Pillay","year":"2020","journal-title":"J. Clin. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Sheinin, M., Jeong, B., Paidi, R.K., and Pahan, K. (2022). Regression of Lung Cancer in Mice by Intranasal Administration of SARS-CoV-2 Spike S1. Cancers, 14.","DOI":"10.3390\/cancers14225648"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jobm.202000537","article-title":"SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights","volume":"61","author":"Kadam","year":"2021","journal-title":"J. Basic Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"118056","DOI":"10.1016\/j.lfs.2020.118056","article-title":"Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination","volume":"257","author":"Sternberg","year":"2020","journal-title":"Life Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nsmb.3293","article-title":"Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy","volume":"23","author":"Walls","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jmv.26320","article-title":"SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen","volume":"93","author":"Wang","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_8","first-page":"833","article-title":"Be aware of SARS-CoV-2 spike protein: There is more than meets the eye","volume":"35","author":"Theoharides","year":"2021","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/imm.12462","article-title":"Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus","volume":"145","author":"Guo","year":"2015","journal-title":"Immunology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1002\/1873-3468.13691","article-title":"State-of-the-art human adenovirus vectorology for therapeutic approaches","volume":"593","author":"Gao","year":"2019","journal-title":"FEBS Lett."},{"key":"ref_11","first-page":"221","article-title":"Efficacy and safety of COVID-19 vaccines: A systematic review","volume":"23","author":"Xing","year":"2021","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"804945","DOI":"10.3389\/fimmu.2022.804945","article-title":"Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/d41586-021-02385-x","article-title":"India\u2019s DNA COVID vaccine is a world first-more are coming","volume":"597","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients\u2019 B Cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 Vaccines: Status Report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/22221751.2021.1887767","article-title":"A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques","volume":"10","author":"Li","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV--a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/jmv.26541","article-title":"N-terminally truncated nucleocapsid protein of SARS-CoV-2 as a better serological marker than whole nucleocapsid protein in evaluating the immunogenicity of inactivated SARS-CoV-2","volume":"93","author":"Yue","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Greaney, A.J., Loes, A.N., Gentles, L.E., Crawford, K.H.D., Starr, T.N., Malone, K.D., Chu, H.Y., and Bloom, J.D. (2021). The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD. bioRxiv.","DOI":"10.1101\/2021.04.14.439844"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.4049\/jimmunol.2001420","article-title":"Evaluation of Cellular and Serological Responses to Acute SARS-CoV-2 Infection Demonstrates the Functional Importance of the Receptor-Binding Domain","volume":"206","author":"Mantus","year":"2021","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbrc.2004.09.106","article-title":"Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: Implication for developing subunit vaccine","volume":"324","author":"He","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Deng, S., Liang, H., Chen, P., Li, Y., Li, Z., Fan, S., Wu, K., Li, X., Chen, W., and Qin, Y. (2022). Viral Vector Vaccine Development and Application during the COVID-19 Pandemic. Microorganisms, 10.","DOI":"10.3390\/microorganisms10071450"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"697074","DOI":"10.3389\/fimmu.2021.697074","article-title":"Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1080\/21645515.2017.1419108","article-title":"Development of novel vaccine vectors: Chimpanzee adenoviral vectors","volume":"14","author":"Guo","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cell.2020.08.025","article-title":"Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19","volume":"183","author":"Kaneko","year":"2020","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1002\/eji.201040539","article-title":"IFN-\u03b3 and IL-12 synergize to convert in vivo generated Th17 into Th1\/Th17 cells","volume":"40","author":"Lexberg","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41421-021-00360-4","article-title":"Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection","volume":"7","author":"Liu","year":"2021","journal-title":"Cell Discov."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/2\/429\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:33:32Z","timestamp":1760121212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/2\/429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["vaccines11020429"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11020429","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2023,2,13]]}}}